Paul Hastings LLP advised Orchestra BioMed on the deal. Orchestra BioMed, a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced the closing of a $110...
Orchestra BioMed’s $110 Million Series D Financing
Orchestra BioMed’s Collaboration with Medtronic
Paul Hastings LLP advised Orchestra BioMed on the deal. Orchestra BioMed announced a strategic collaboration with Medtronic to develop Orchestra BioMed’s BackBeat Cardiac Neuromodulation Therapy™ (CNT™) as...
Orchestra BioMed’s Merger with Health Sciences Acquisitions Corporation 2
Paul Hastings LLP advised Orchestra BioMed on the deal. Loeb & Loeb LLP served as legal counsel for HSAC2. Latham & Watkins LLP represented the capital...